Advertisement

Drugs

, Volume 78, Issue 1, pp 123–130 | Cite as

Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis

Adis Drug Evaluation
  • 392 Downloads

Abstract

Fumaric acid esters (FAEs) have been used in the treatment of psoriasis in some European countries for over 20 years, and are recommended in the European guidelines for the management of moderate to severe plaque psoriasis. Dimethyl fumarate (Skilarence®; hereafter referred to as DMF) is an orally administered FAE indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy; unlike other available FAEs, it is not formulated in combination with monoethyl fumarate salts. EU approval was based on results of the phase III BRIDGE trial, and supported by previous publications of FAE preparations, including a combination of FAEs containing dimethyl fumarate and monoethyl fumarate salts (DMF/MEF; Fumaderm®). In the BRIDGE trial, DMF was superior to placebo in terms of the proportion of patients achieving a ≥ 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75) and a Physician Global Assessment score of 0 (clear) or 1 (almost clear) at week 16. DMF was also noninferior to DMF/MEF for PASI 75 at week 16. Patients receiving DMF also reported clinically meaningful improvements in body surface area involvement and health-related quality of life. The safety profile of DMF was similar to that of DMF/MEF, and no major or unexpected safety concerns were identified. The most common adverse events (flushing and gastrointestinal disorders) occurred mainly during the first few weeks of treatment. Currently available data indicate that DMF is an effective oral systemic treatment option for patients with moderate to severe plaque psoriasis.

Notes

Acknowledgements

During the peer review process, the manufacturer of DMF was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/D15CF06028AE6C06.

References

  1. 1.
    Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504–13.PubMedPubMedCentralGoogle Scholar
  2. 2.
    World Health Organization. Global report on psoriasis. 2016. http://www.who.int. Accessed 8 Dec 2017.
  3. 3.
    Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Balak D. Fumaric acid esters in the management of psoriasis. Psoriasis Targ Ther. 2015;2015(1):9–23.CrossRefGoogle Scholar
  5. 5.
    Okpara E. Dimethyl fumarate for moderate to severe chronic plaque psoriasis. Newcastle: Regional Drug & Therapeutics Centre; 2017.Google Scholar
  6. 6.
    Smith D. Fumaric acid esters for psoriasis: a systematic review. Ir J Med Sci. 2017;186(1):161–77.CrossRefPubMedGoogle Scholar
  7. 7.
    European Medicines Agency. Summary of product characteristics: Skilarence 30 mg gastro-resistant tablets, Skilarence 120 mg gastro-resistant tablets. 2017. http://www.ema.europa.eu. Accessed 8 Dec 2017.
  8. 8.
    European Medicines Agency. Assessment report: Skilarence. 2017. http://www.ema.europa.eu. Accessed 8 Dec 2017.
  9. 9.
    Lehmann JC, Listopad JJ, Rentzsch CU, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol. 2007;127(4):835–45.CrossRefPubMedGoogle Scholar
  10. 10.
    Gesser B, Johansen C, Rasmussen MK, et al. Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol. 2007;127(9):2129–37.CrossRefPubMedGoogle Scholar
  11. 11.
    Ockenfels HM, Schultewolter T, Ockenfels G, et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998;139(3):390–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Onderdijk AJ, Balak DMW, Baerveldt EM, et al. Regulated genes in psoriatic skin during treatment with fumaric acid esters. Br J Dermatol. 2014;171(4):732–41.CrossRefPubMedGoogle Scholar
  13. 13.
    Bovenschen HJ, Langewouters AM, van de Kerkhof PC. Dimethylfumarate for psoriasis: pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study. Am J Clin Dermatol. 2010;11(5):343–50.CrossRefPubMedGoogle Scholar
  14. 14.
    Litjens NHR, van Strijen E, van Gulpen C, et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 2004;4:22.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rostami-Yazdi M, Clement B, Schmidt TJ, et al. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol. 2009;129(1):231–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Rostami-Yazdi M, Clement B, Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res. 2010;302(7):531–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Nast A, Boehncke WH, Mrowietz U, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res. 2012;304(2):87–113.CrossRefPubMedGoogle Scholar
  18. 18.
    Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm®- and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017;176(3):615–23.CrossRefPubMedGoogle Scholar
  19. 19.
    Mrowietz U, Szepietowski J, Loewe R, et al. Clinical efficacy of LAS41008 (dimethyl fumarate) in pre-treated vs naive patients with moderate-to-severe chronic plaque psoriasis: post-hoc analysis of the BRIDGE study [abstract no. P1848 plus poster]. In: European Academy of Dermatology and Venerology. 2017.Google Scholar
  20. 20.
    Mrowietz U, Szepietowski J, Loewe R, et al. LAS41008 (dimethyl fumarate) for psoriasis: analysis of the efficacy of treatment according to severity of disease at baseline [abstract no. P1846 plus poster]. In: European Academy of Dermatology and Venereology. 2017.Google Scholar
  21. 21.
    Van de Kerkhof P, Szepietowski JC, Loewe R, et al. Treatment with LAS41008 (dimethyl fumarate) improves health-related quality of life and has a positive impact on the patient benefit index in adults with moderate-to-severe chronic plaque psoriasis: results of the BRIDGE study [abstract P1998 plus poster]. In: European Academy of Dermatology and Venerology. 2016.Google Scholar
  22. 22.
    Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol. 1994;30(6):977–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Nieboer C, de Hoop D, van Loenen AC, et al. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol. 1989;20(4):601–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Nugteren-Huying WM, van der Schroeff JG, Hermans J, et al. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 1990;22(2 Pt 1):311–2.CrossRefPubMedGoogle Scholar
  25. 25.
    Fallah Arani S, Neumann H, Hop WC, et al. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br J Dermatol. 2011;164(4):855–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Nieboer C, de Hoop D, Langendijk PN, et al. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica. 1990;181(1):33–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Walker F, Adamczyk A, Kellerer C, et al. Fumaderm in daily practice for psoriasis: dosing, efficacy and quality of life. Br J Dermatol. 2014;171(5):1197–205.CrossRefPubMedGoogle Scholar
  28. 28.
    Inzinger M, Weger W, Heschl B, et al. Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions. J Eur Acad Dermatol Venereol. 2013;27(7):861–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol. 2005;153(3):549–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Brewer L, Rogers S. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol. 2007;32(3):246–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Reich K, Thaci D, Mrowietz U, et al. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis—a retrospective study (FUTURE). J Dtsch Dermatol Ges. 2009;7(7):603–11.PubMedGoogle Scholar
  32. 32.
    Thaci D, Weisenseel P, Philipp S, et al. Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions—a retrospective evaluation (FACTS). J Dtsch Dermatol Ges. 2013;11(5):429–35.PubMedGoogle Scholar
  33. 33.
    Thio HB, van der Schroeff JG, Nugteren-Huying WM, et al. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. J Eur Acad Dermatol Venereol. 1995;4(1):35–40.CrossRefGoogle Scholar
  34. 34.
    Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol. 1992;27(5 Pt 1):769–71.CrossRefPubMedGoogle Scholar
  35. 35.
    Lijnen R, Otters E, Balak D, et al. Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study. J Dermatol Treat. 2016;27(1):31–6.CrossRefGoogle Scholar
  36. 36.
    Balak DMW, Hajdarbegovic E, Bramer WM, et al. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients. J Eur Acad Dermatol Venereol. 2017;31(9):1475–82.CrossRefPubMedGoogle Scholar
  37. 37.
    Gieselbach RJ, Muller-Hansma AH, Wijburg MT, et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol. 2017;264(6):1155–64.CrossRefPubMedGoogle Scholar
  38. 38.
    Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from the German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875–83.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol. 2003;149(2):363–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris—update 2015—short version—EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–94.CrossRefPubMedGoogle Scholar
  41. 41.
    Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85.CrossRefPubMedGoogle Scholar
  42. 42.
    Zweegers J, de Jong EM, Nijsten TE, et al. Summary of the Dutch S3-guidelines on the treatment of psoriasis 2011. Dutch Society of Dermatology and Venereology. Dermatol Online J. 2014;20(3).Google Scholar
  43. 43.
    Arnold T, Schaarschmidt ML, Herr R, et al. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges. 2016;14(11):1089–99.CrossRefPubMedGoogle Scholar
  44. 44.
    Ismail N, Collins P, Rogers S, et al. Drug survival of fumaric acid esters for psoriasis: a retrospective study. Br J Dermatol. 2014;171(2):397–402.CrossRefPubMedGoogle Scholar
  45. 45.
    Sticherling M, Mrowietz U, Augustin M, et al. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Br J Dermatol. 2017;177(4):1024–32.CrossRefPubMedGoogle Scholar
  46. 46.
    Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(3):513–26.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations